ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Health Technology

Taisho Pharmaceutical Holdings Co., Ltd.

Business Summary

Taisho Pharmaceutical Holdings Co. Ltd. engages in the management and administration of its group companies that manufactures and sells over-the-counter (OTC) drugs, foods, and other goods, etc. It operates through the following segments: Self-Medication and Prescription Pharmaceutical. The Self-Medication segment conducts research and development (R&D), manufacturing and sale of over-the-counter drugs, quasi-drugs, food, and general medical and hygiene supplies. The Prescription Pharmaceutical segment handles R&D, manufacturing, and sale of ethical drugs. It also provides the manufacture and sale of prescription pharmaceuticals; and businesses incidental or related thereto. The company was founded on October 3, 2011 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2020 JPYUSD
Revenue288,720M2,655.48M
Gross Profit180,383M1,659.06M
Operating income21,460M197.37M
Income before tax30,311M278.78M
Net income20,531M188.83M
EBITDA38,155M350.92M
Diluted EPS256.932.36
Dividends Per Share1101.01
Total Assets853,051M7,901.91M
Total liabilities111,341M1,031.36M
Total equity712,077M6,596.05M
Operating cash flow41,992M386.21M
Currency in JPYCurrency in USD

Historical Data

 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 289,956M 279,750M 280,138M 261,369M 288,720M
Gross Profit 176,813M 178,225M 182,984M 170,163M 180,383M
Operating income 28,878M 31,965M 36,977M 31,212M 21,460M
Income before tax 35,809M 41,956M 48,070M 64,484M 30,311M
Net income 22,473M 28,781M 31,679M 48,594M 20,531M
EBITDA 41,351M 43,635M 48,357M 42,502M 38,155M
Diluted EPS 277.60 359.93 396.20 608.22 256.93
Dividends Per Share 100 110 110 110 110
Total Assets 759,049M 771,222M 799,616M 821,782M 853,051M
Total liabilities 115,922M 106,132M 108,296M 97,643M 111,341M
Total equity 629,249M 649,938M 675,231M 712,972M 712,077M
Operating cash flow 43,058M 40,066M 39,852M 19,222M 41,992M
 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 2,414.60M 2,583.40M 2,527.58M 2,356.91M 2,655.48M
Gross Profit 1,472.40M 1,645.85M 1,650.99M 1,534.45M 1,659.06M
Operating income 240.48M 295.18M 333.62M 281.45M 197.37M
Income before tax 298.19M 387.45M 433.71M 581.48M 278.78M
Net income 187.14M 265.78M 285.82M 438.19M 188.83M
EBITDA 344.34M 402.95M 436.30M 383.26M 350.92M
Diluted EPS 2.31 3.32 3.57 5.48 2.36
Dividends Per Share 0.83 1.01 0.99 0.99 1.01
Total Assets 6,753.40M 6,921.13M 7,518.71M 7,424.51M 7,901.91M
Total liabilities 1,031.38M 952.45M 1,018.29M 882.17M 1,031.36M
Total equity 5,598.54M 5,832.70M 6,349.13M 6,441.45M 6,596.05M
Operating cash flow 358.56M 369.99M 359.56M 173.33M 386.21M

Valuation Measures

Mar 2020
PER25.81
ROA2.45%
ROE2.88%
Operating margin7.43%
Profit margin7.11%

Key executives

  • President & Representative Director: Akira Uehara
  • Director, Head-Audit, Finance & Legal Affairs: Ken Uehara
  • Finance Manager: Masahiro Mino
  • Head-Information Technology Planning: Osamu Kitatani
  • Director & Executive Vice President: Shigeru Uehara

Shareholders

  • The Uehara Memorial Foundation (17.6%)
  • UEHARA SHOJI (9.1%)
  • Taisho Pharmaceutical Holdings Co., Ltd. (6.1%)
  • Sumitomo Mitsui Financial Group, Inc. (5.4%)
  • Uehara Museum Foundation (4.5%)
  • Mitsubishi UFJ Financial Group, Inc. (4.2%)
  • UEHARA AKIRA (2.5%)
  • Kajima Corp. (1.9%)
  • Sumitomo Chemical Pension Fund (1.7%)
  • Sumitomo Chemical Co., Ltd. (1.6%)

Contact Details

Related Companies

  • Kosei SA de CV
  • DHG Pharmaceutical Joint Stock Company
  • Biofermin Pharmaceutical Co., Ltd.
  • Taisho Pharmaceutical Co., Ltd.

Competitors

  • BioGaia AB Class B
  • Monster Beverage Corporation
  • LT Group, Inc.
  • VistaGen Therapeutics, Inc.
Last Updated on 12 Aug, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media